Name | (3R)-1-[(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]pyrrolidin-3-ol |
---|---|
Synonyms |
(3R)-1-[(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]-3-pyrrolidinol
(1R,2R)-2-[(3R)-hydroxypyrrolidinyl]-1-(3,4-dimethoxyphenethoxy)cyclohexane Kynapid Vernakalant 3-Pyrrolidinol, 1-[(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]-, (3R)- Brinavess (1R-{2R-[2-(3,4-dimethoxyphenyl)-ethoxy]-cyclohex-2-yl})-pyrrolidin-3R-ol (3R)-1-{(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl}pyrrolidin-3-ol RSD 1235 (3R)-1-{(1R,2R)-2-[2-(3,4-Dimethoxyphenyl)ethoxy]cyclohexyl}-3-pyrrolidinol 1R-(2R-(2-(3,4-dimethoxy-phenyl)-ethoxy)-cyclohexyl)-pyrrolidin-3R-ol Vernakalant [INN:BAN] UNII-9G468C8B13 cc-484 Vernakalant [INN] (3R)-1-{(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl}pyrrolidinol |
Description | Vernakalant(RSD-1235) is an investigational mixed ion channel blocker that can terminate acute atrial fibrillation (AF) in humans at 2 to 5 mg/kg and may be more atrial-selective than available agents; in treatment of antiarrhythmic.IC50 value:Target: |
---|---|
Related Catalog | |
References |
[3]. Vernakalant. Too dangerous in atrial fibrillation.Prescrire Int. 2012 May;21(127):119-22. |
Density | 1.1±0.1 g/cm3 |
---|---|
Boiling Point | 479.0±45.0 °C at 760 mmHg |
Molecular Formula | C20H31NO4 |
Molecular Weight | 349.464 |
Flash Point | 243.5±28.7 °C |
Exact Mass | 349.225311 |
PSA | 51.16000 |
LogP | 2.40 |
Vapour Pressure | 0.0±1.3 mmHg at 25°C |
Index of Refraction | 1.557 |
~77% 794466-70-9 |
Literature: CARDIOME PHARMA CORP. Patent: WO2006/88525 A1, 2006 ; Location in patent: Page/Page column 118; 127-128 ; |
~% 794466-70-9 |
Literature: ALPHORA RESEARCH INC.; GORIN, Boris; DIXON, Craig Edward; OUDENES, Jan; BEJAN, Elena Valentina; KINSMAN, Aaron Cleveland Patent: WO2012/40846 A1, 2012 ; Location in patent: Page/Page column 22-23 ; |
~% 794466-70-9 |
Literature: ASTELLAS PHARMA INC. Patent: WO2006/75778 A1, 2006 ; Location in patent: Page/Page column 26-28 ; |
~% 794466-70-9 |
Literature: Limanto, John; Ashley, Eric R.; Yin, Jingjun; Beutner, Gregory L.; Grau, Brendan T.; Kassim, Amude M.; Kim, Mary M.; Klapars, Artis; Liu, Zhijian; Strotman, Hallena R.; Truppo, Matthew D. Organic Letters, 2014 , vol. 16, # 10 p. 2716 - 2719 |
~% 794466-70-9 |
Literature: Limanto, John; Ashley, Eric R.; Yin, Jingjun; Beutner, Gregory L.; Grau, Brendan T.; Kassim, Amude M.; Kim, Mary M.; Klapars, Artis; Liu, Zhijian; Strotman, Hallena R.; Truppo, Matthew D. Organic Letters, 2014 , vol. 16, # 10 p. 2716 - 2719 |
~% 794466-70-9 |
Literature: Limanto, John; Ashley, Eric R.; Yin, Jingjun; Beutner, Gregory L.; Grau, Brendan T.; Kassim, Amude M.; Kim, Mary M.; Klapars, Artis; Liu, Zhijian; Strotman, Hallena R.; Truppo, Matthew D. Organic Letters, 2014 , vol. 16, # 10 p. 2716 - 2719 |
~% 794466-70-9 |
Literature: CARDIOME PHARMA CORP.; ROTH, Carol, J. Patent: WO2006/138673 A2, 2006 ; Location in patent: Page/Page column 49; 74-75 ; |
~% 794466-70-9 |
Literature: ALPHORA RESEARCH INC.; GORIN, Boris; DIXON, Craig Edward; OUDENES, Jan; BEJAN, Elena Valentina; KINSMAN, Aaron Cleveland Patent: WO2012/40846 A1, 2012 ; Location in patent: Page/Page column 19 ; |
Precursor 6 | |
---|---|
DownStream 0 |